Inventory Record Inaccuracy: An Empirical Analysis

Nicole  DeHoratius; Ananth   Raman

Journal Article | Management Science | April 2008

Inventory Record Inaccuracy: An Empirical Analysis

by Nicole DeHoratius and Ananth Raman

Abstract

This study explores the systematic variation in inventory record inaccuracy (IRI) observed both within and across stores. Traditional inventory models, with a few exceptions, do not account for the existence of IRI and those that do treat record inaccuracy as random. Examining nearly 370,000 inventory records from 37 stores of one retailer, we found 65% to be inaccurate. That is, the recorded inventory quantity of an item fails to match the quantity found in the store. We identify factors associated with this inaccuracy that are stock keeping unit- (SKU) and store-specific. SKU-specific factors such as item cost, selling quantity, and method of distribution account for the observed variation in IRI within stores. Store-specific factors such as the density and variety of inventory observed at each store account for the variation in IRI across stores.

Keywords: Information Management; Measurement and Metrics; Logistics; Retail Industry;

Format: Print

Find at Harvard

Citation:

DeHoratius, Nicole, and Ananth Raman. "Inventory Record Inaccuracy: An Empirical Analysis." Management Science 54, no. 4 (April 2008).

Celebrated as one of the world's premiere luxury hotel brands, Oberoi Hotels attracts and serves some of the most quality sensitive guests in the world. The case considers the challenge of how an organization with a standardized service model can repeatedly delight customers whose expectations grow with every interaction. To explore this question, the case details the design elements of Oberoi's complex service operation, including its approaches to employee management and continuous improvement, as well as the dynamics of service competition in a rapidly growing market.

In 2016, David Hysong, at age 27, found out he had a rare, incurable cancer. Rather than wait around to die, Hysong, a recent graduate of Harvard Divinity School, decided to launch a biotechnology company called Shepherd Therapeutics to development treatments for his and other rare cancers. Two years later, the company had several drugs in promising stages of development but were at least 3 to 5 years away from commercialization, if they made it through clinical trials successfully. Only about 4% of drugs that enter clinical trials receive U.S. FDA approval. It is October 2018, and Shepherd is running out of money. Hysong needs to raise $5 million to fund operations for 2019 and at least $20 million for the following few years. But the company is too early to attract the type of venture capital he needs. Even if he got financing, Hysong worried that the company’s mission could be compromised by investors more interested in a return on their investment than saving lives, and he worried about the scaling challenges ahead.

Faculty & Research

Inventory Record Inaccuracy: An Empirical Analysis

Abstract

Citation:

About the Author

More from the Author